These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon. Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Seibold JR; Jageneau AH Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102 [TBL] [Abstract][Full Text] [Related]
10. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma. Engelhart M Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193 [TBL] [Abstract][Full Text] [Related]
11. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial. Lukác J; Rovenský J; Tauchmannová H; Zitnan D Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837 [TBL] [Abstract][Full Text] [Related]
12. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases]. Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558 [TBL] [Abstract][Full Text] [Related]
13. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker. Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173 [No Abstract] [Full Text] [Related]
14. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon. Dormandy JA; Berent A; Downes SJ Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Roald OK; Seem E Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198 [TBL] [Abstract][Full Text] [Related]
16. Treatment of the Raynaud's phenomenon with piracetam. Moriau M; Lavenne-Pardonge E; Crasborn L; von Frenckell R; Col-Debeys C Arzneimittelforschung; 1993 May; 43(5):526-35. PubMed ID: 8328997 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon. Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829 [TBL] [Abstract][Full Text] [Related]
18. Ketanserin and capillary flow in Raynaud's phenomenon. Tooke JE; Williams SA; Rawlinson DW; Black C Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546 [TBL] [Abstract][Full Text] [Related]
19. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon. Longstaff J; Gush R; Williams EH; Jayson MI J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071 [TBL] [Abstract][Full Text] [Related]
20. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. Igarashi M; Okuda T; Oh-i T; Koga M J Dermatol; 2000 Oct; 27(10):643-50. PubMed ID: 11092268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]